Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 269 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Systemic Sclerosis, Scleroderma Clear all

Conditions: Systemic Sclerosis, Scleroderma
Interventions: STI571; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 3
States / cities: Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts

Conditions: Interstitial Lung Diseases
Interventions: Not listed
Lead sponsor: Pulmonary Care and Research Collaborative Limited; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Arthritis, Osteoarthritis Hand, Scleroderma, Systemic, Scleroderma, Diffuse, Rheumatoid Arthritis
Interventions: Custom Fabricated Splint; Other
Lead sponsor: Giovanna Fichera; Other
Eligibility: 18 Years to 100 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Troy, New York

Conditions: Scleroderma, Sclerodactyly, Systemic Sclerosis
Interventions: hyaluronidase; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Systemic Sclerosis, Scleroderma, Interstitial Lung Diseases
Interventions: CABA-201; Biological
Lead sponsor: Cabaletta Bio; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 10
States / cities: New Haven, Connecticut • Jacksonville, Florida • Chicago, Illinois + 6 more

Conditions: Scleroderma
Interventions: MEDI-546; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 11
States / cities: Los Angeles, California • Boston, Massachusetts • Ann Arbor, Michigan + 7 more

Conditions: Morphea, Plaque Form
Interventions: Sarilumab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Scleroderma
Interventions: Internet-based self-management program, Scleroderma book; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Morphea, Scleroderma, Localized, Scleroderma
Interventions: FCX-013, veledimex; Genetic · Drug
Lead sponsor: Castle Creek Biosciences, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Scleroderma, Systemic Sclerosis
Interventions: Divalproex sodium; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Scleroderma, Systemic
Interventions: Imatinib mesylate; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Scleroderma, Connective Tissue Diseases
Interventions: Oral bovine type I collagen, Placebo; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 12
States / cities: Birmingham, Alabama • Los Angeles, California • Farmington, Connecticut + 9 more

Conditions: Scleroderma
Interventions: MEDI-551, Placebo, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 12
States / cities: Loma Linda, California • Redwood City, California • Farmington, Connecticut + 9 more

Conditions: Diffuse Cutaneous Systemic Sclerosis
Interventions: Patients will be randomized to receive EHP-101 or Placebo; Drug
Lead sponsor: Emerald Health Pharmaceuticals; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 13
States / cities: Phoenix, Arizona • Huntington Beach, California • Los Angeles, California + 9 more

Conditions: Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Scleroderma Associated Pulmonary Arterial Hypertension, Appetite Suppressant Associate PAH
Interventions: Not listed
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: Up to 90 Years
Enrollment: 1,899 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2032
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Scleroderma, Systemic, Sclerosis
Interventions: currently available therapy in the community; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 69 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diffuse Cutaneous Systemic Sclerosis
Interventions: Placebo, Ianalumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 14
States / cities: Mesa, Arizona • Los Angeles, California • Newport Beach, California + 11 more

Conditions: Scleroderma
Interventions: Resilience-based, Energy Management to Enhance Wellbeing (RENEW); Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Scleroderma
Interventions: UVA-1 Phototherapy, UV-Blocking Glove; Device · Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Scleroderma
Interventions: Hematopoietic stem cell transplantation; Biological
Lead sponsor: Richard Burt, MD; Other
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diffuse Cutaneous Systemic Sclerosis
Interventions: Lenabasum 5 mg, Lenabasum 20 mg, Placebo oral capsule; Drug · Other
Lead sponsor: Corbus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 27
States / cities: La Jolla, California • Los Angeles, California • Palo Alto, California + 21 more

Conditions: Systemic Sclerosis
Interventions: Nemolizumab, Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Arlington, Texas

Conditions: Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2028
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Diffuse Cutaneous Systemic Sclerosis
Interventions: Belumosudil; Drug
Lead sponsor: Kadmon, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 3 more

Search by objective public record fields.

Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic Sclerosis

Monitoring and Evaluation Study of Project ECHO for ILD

Novel Splinting Technique Using 3D Models

Hyaluronidase Injections for Sclerodactyly in Patients With Scleroderma

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma

Study to Assess Sarilumab in Halting Progression of Morphea

Taking Charge of Systemic Sclerosis

A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)

Divalproex Sodium in the Treatment of the Cutaneous Manifestations of Scleroderma

Imatinib in Systemic Sclerosis

Oral Type I Collagen for Relieving Scleroderma

A Study of the Safety and Tolerability of MEDI-551 in Scleroderma

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis

Hormonal, Metabolic, and Signaling Interactions in PAH

SCOT Scleroderma Treatment Alternative Registry (STAR Registry)

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

Feasibility and Preliminary Effects of the Resilience-based, Energy Management to Enhance Wellbeing in Systemic Sclerosis (RENEW) Intervention

UVA-1 for Treatment of Skin Tightening and Improvement of Hand Function in Scleroderma

Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Systemic Sclerosis

Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis

A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis

Comparative Autoantibody and Immunologic Cell Marker Study

Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis